（文章来源：证券日报） 证券日报网讯 11月19日晚间，睿智医药发布公告称，公司于2025年9月3日召开第六届董事会第十一次 会议，审议通过了《关于全资子公司与专业投资机构共同投资的议案》。为借助专业投资机构的投资能 力、资金优势及风险控制能力，赋能创新药产业协同，公司全资子公司北海睿智创业投资有限公司（简 称"北海睿智"）与专业投资机构深圳市投控东海投资有限公司（简称"投控东海""基金管理人"）及其他 有限合伙人深圳市罗湖产业促进合伙企业（有限合伙）拟共同出资设立深圳市罗湖东海睿智医药产业合 伙企业（有限合伙）（简称"合伙企业"或"基金"），全体合伙人认缴出资总额为人民币20，000万元， 其中北海睿智作为有限合伙人以自有资金出资人民币5，800万元，占认缴出资总额的29%。公司于近日 收到通知，合伙企业已根据《中华人民共和国证券投资基金法》和《私募投资基金监督管理暂行办法》 等法律法规的要求，在中国证券投资基金业协会完成了备案手续，并取得了《私募投资基金备案证 明》。 ...

Group 1 - The A-share market has recently experienced a significant upward trend, particularly in the pharmaceutical sector, which has shown a year-to-date increase of 60.77%, outperforming the overall A-share index by 22.14% as of September 2, 2025 [1] - The performance of pharmaceutical-themed mutual funds has also been strong, with notable returns since the beginning of the year, highlighting the growing interest in this sector [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked highly among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1][2] Group 2 - The innovative drug sector in China is expected to have significant value discovery potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2] - The investment approach of Zhongyin Fund's manager, Zheng Ning, focuses on filtering out market noise and concentrating on long-term implicit returns, which is considered a sustainable investment strategy [2] Group 3 - Zhongyin Hong Kong Stock Connect Medical A, managed by Zheng Ning since December 29, 2023, has shown a net value growth rate of 70.08% in the first half of 2025, significantly outperforming its benchmark [3] - Zhongyin Innovation Medical Mixed A, also managed by Zheng Ning, has demonstrated strong performance since its inception, with a net value growth rate of 54.08% in the first half of 2025 [4][5]